These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 10188885)
1. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis. Boher JM; Pujol JL; Grenier J; Daurès JP Br J Cancer; 1999 Mar; 79(9-10):1419-27. PubMed ID: 10188885 [TBL] [Abstract][Full Text] [Related]
2. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951 [TBL] [Abstract][Full Text] [Related]
3. [Neuron-specific enolase (NSE) in the surveillance of small cell cancers. An evaluation of the prognostic information using Markov's model]. Pujol JL; Boher JM; Grenier J; Quantin X; Saffont L; Daurès JP Rev Mal Respir; 1998 Sep; 15(4):519-25. PubMed ID: 9805763 [TBL] [Abstract][Full Text] [Related]
4. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660 [TBL] [Abstract][Full Text] [Related]
5. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study]. Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457 [TBL] [Abstract][Full Text] [Related]
6. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727 [TBL] [Abstract][Full Text] [Related]
8. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE. Ebert W; Hoppe M; Muley T; Drings P Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552 [TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S; Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326 [TBL] [Abstract][Full Text] [Related]
10. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Ebert W; Muley T; Drings P Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537 [TBL] [Abstract][Full Text] [Related]
11. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Ray P; Quantin X; Grenìer J; Pujol JL Cancer Detect Prev; 1998; 22(4):293-304. PubMed ID: 9674872 [TBL] [Abstract][Full Text] [Related]
12. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
13. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Ebert W; Muley T Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217 [TBL] [Abstract][Full Text] [Related]
14. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246 [TBL] [Abstract][Full Text] [Related]
15. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651 [TBL] [Abstract][Full Text] [Related]
17. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381 [TBL] [Abstract][Full Text] [Related]
18. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443 [TBL] [Abstract][Full Text] [Related]
19. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Muley T; Dienemann H; Ebert W Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383 [TBL] [Abstract][Full Text] [Related]
20. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Muley T; Dienemann H; Ebert W Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]